QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:ARAV

Aravive (ARAV) Stock Forecast, Price & News

$0.13
0.00 (0.00%)
(As of 09/28/2023 ET)
Compare
Today's Range
$0.13
$0.14
50-Day Range
$0.11
$1.65
52-Week Range
$0.11
$2.46
Volume
1.79 million shs
Average Volume
2.66 million shs
Market Capitalization
$9.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.17

Aravive MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
7,643.1% Upside
$10.17 Price Target
Short Interest
Bearish
9.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.52
Upright™ Environmental Score
News Sentiment
0.17mentions of Aravive in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.61) to ($0.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars


ARAV stock logo

About Aravive (NASDAQ:ARAV) Stock

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

ARAV Price History

ARAV Stock News Headlines

Aravive, Inc. (NASDAQ:ARAV) Receives $10.17 Average PT from Analysts
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Cantor Fitzgerald Downgrades Aravive
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
William Blair Downgrades Aravive (ARAV)
H.C. Wainwright downgrades Aravive (ARAV) to a Hold
Why Is Aravive Stock Sinking Today?
Why Is Aravive (ARAV) Stock Down 58% Today?
The Latest Analyst Ratings for Aravive
ARAV Jul 2023 7.500 call
See More Headlines
Receive ARAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

ARAV Company Calendar

Last Earnings
8/21/2023
Today
9/28/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARAV
Fax
N/A
Employees
23
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.17
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+7,649.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-76,320,000.00
Net Margins
-834.54%
Pretax Margin
-834.54%

Debt

Sales & Book Value

Annual Sales
$9.14 million
Book Value
$0.18 per share

Miscellaneous

Free Float
29,131,000
Market Cap
$9.65 million
Optionable
Optionable
Beta
2.41
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Fredric N. Eshelman Pharm.D. (Age 74)
    Exec. Chairman
    Comp: $95k
  • Dr. Gail F. McIntyre CH (ASCP) (Age 60)
    DABT, Ph.D., Pres, CEO & Director
    Comp: $803.99k
  • Mr. Rudy C. Howard B.A. (Age 65)
    CPA, CPA, Chief Financial Officer
    Comp: $500.26k
  • Dr. Jeffrey L. Cleland Ph.D. (Age 58)
    Co-Founder
  • Dr. Joshua Silverman Ph.D.
    Co-Founder
  • Mr. Marek Ciszewski J.D.
    VP of Investor Relations
  • Dr. Randy L. Anderson
    Sr. VP of Data Sciences
  • Dr. Robert B. Geller M.D. (Age 69)
    Chief Medical Officer
  • Ms. Carolina Petrini
    Chief Commercial Officer













ARAV Stock - Frequently Asked Questions

Should I buy or sell Aravive stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ARAV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARAV, but not buy additional shares or sell existing shares.
View ARAV analyst ratings
or view top-rated stocks.

What is Aravive's stock price forecast for 2023?

6 analysts have issued 12-month target prices for Aravive's shares. Their ARAV share price forecasts range from $2.00 to $18.00. On average, they expect the company's share price to reach $10.17 in the next twelve months. This suggests a possible upside of 7,649.0% from the stock's current price.
View analysts price targets for ARAV
or view top-rated stocks among Wall Street analysts.

How have ARAV shares performed in 2023?

Aravive's stock was trading at $1.32 at the start of the year. Since then, ARAV shares have decreased by 90.1% and is now trading at $0.1312.
View the best growth stocks for 2023 here
.

Are investors shorting Aravive?

Aravive saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 7,300,000 shares, an increase of 62.9% from the August 31st total of 4,480,000 shares. Based on an average trading volume of 6,950,000 shares, the days-to-cover ratio is currently 1.1 days.
View Aravive's Short Interest
.

When is Aravive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ARAV earnings forecast
.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) announced its earnings results on Monday, August, 21st. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.18. The company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1 million. Aravive had a negative trailing twelve-month return on equity of 1,865.78% and a negative net margin of 834.54%.

What other stocks do shareholders of Aravive own?
What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Who are Aravive's major shareholders?

Aravive's stock is owned by many different retail and institutional investors. Top institutional shareholders include Affinity Asset Advisors LLC (0.00%), BlackRock Inc. (0.54%), Geode Capital Management LLC (0.51%), Renaissance Technologies LLC (0.36%) and Assenagon Asset Management S.A. (0.03%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah.
View institutional ownership trends
.

How do I buy shares of Aravive?

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $0.13.

How much money does Aravive make?

Aravive (NASDAQ:ARAV) has a market capitalization of $9.65 million and generates $9.14 million in revenue each year. The company earns $-76,320,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com.

This page (NASDAQ:ARAV) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -